Activity of postoperative carboplatin, etoposide, and high‐dose methotrexate in pediatric CNS embryonal tumors: Results of a phase II study in newly diagnosed children

Abstract

The combination of carboplatin, etoposide, and high-dose methotrexate is highly active in pediatric patients with CNS embryonal tumors.

Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG‐921: A phase III combined modality study

“…Because infants are more prone to neurocognitive sequelae of radiation therapy, investigators have attempted to delay or omit CSI altogether 5,23–25; however, results have been disappointing. The current study shows a 3‐year PFS for infant PF‐PNET of 26% and 14% for M0 and M+ disease, respectively.…”

MEDULLOBLASTOMA IN CHILDREN 0–3 YEARS OLD: Forty Years' Experience in Slovenia

“…Survival of children with "high risk" medulloblastoma is still very poor. Hopefully newly developed treatment modalities and Cht combinations will show improvement [9][10][11].…”

Medulloblastomas and central nervous system primitive neuroectodermal tumors

“…When used with etoposide (similar to the PNET-3 study), eventfree survival and overall survival are comparable to cisplatin-containing regimens [25•]. High-dose IV methotrexate, irinotecan, busulfan, melphalan, and thiotepa have all shown activity against MB/PNET [33][34][35]. • The prognosis for patients who have disease recurrence after surgery, radiation, and chemotherapy is poor, although up to 30% to 40% of patients may have favorable outcomes after high-dose chemotherapy with autologous bone marrow/stem cell support [7,35].…”